{ "schema_version": 1, "kind": "condition", "id": "obesity", "name": "Obesity (primary care management)", "category": "chronic", "sources": "eMC SmPC, Wegovy 2.4 mg FlexTouch solution for injection (Novo Nordisk), sections 4.1 and 4.2 · Xenical US prescribing information, Dosage and Administration (DailyMed SetID 6240792b-9224-2d10-e053-2a91aa0a2c3e) · Chamarthi VS, Daley SF. Obesity Medications: Evidence-Based Management. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Updated 2025 Sep 2. Bookshelf ID: NBK618375.", "review_status": "reviewed", "verified_against": "eMC SmPC, Wegovy 2.4 mg FlexTouch solution for injection (Novo Nordisk), sections 4.1 and 4.2 · Xenical US prescribing information, Dosage and Administration (DailyMed SetID 6240792b-9224-2d10-e053-2a91aa0a2c3e) · Chamarthi VS, Daley SF. Obesity Medications: Evidence-Based Management. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Updated 2025 Sep 2. Bookshelf ID: NBK618375.", "verified_date": "2026-08", "treatments": [ { "id": 1271, "generic": "Orlistat", "line": 1, "is_adjunct": false, "form": "oral.solid", "strength_mg": 120.0, "adult_dose": "120 mg three times a day with each main meal containing fat (during or up to 1 hour after the meal)", "adult_duration": null, "dose_source": "Xenical US prescribing information, Dosage and Administration (DailyMed SetID 6240792b-9224-2d10-e053-2a91aa0a2c3e)", "rationale": "Pancreatic and gastric lipase inhibitor that blocks absorption of dietary fat, used alongside a reduced-calorie diet for weight management.", "cautions": [ "CONTRAINDICATED in chronic malabsorption syndrome and cholestasis.", "Omit dose if a meal is missed or contains no fat.", "Common GI side effects include oily spotting, flatus with discharge, and fecal urgency.", "Take a multivitamin containing fat-soluble vitamins (A, D, E, K) at bedtime.", "Contraindicated during pregnancy." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not recommended for children under 12 years; specialist use only 12-16 years. Xenical US prescribing information section 8.4 says \"Safety and effectiveness in pediatric patients below the age of 12 have not been established\" and \"The safety and efficacy of XENICAL have been evaluated in obese adolescent patients aged 12 to 16 years\".", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "FATLOSE 120 MG 10 CAP.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EL-OBOUR > REPHARMA", "price_egp": 20.0, "pack_count": 10, "unit_price": 2.0, "strength_mg": 120.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CUT DOWN 120 MG 20 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SABAA > NOVELL PHARMA", "price_egp": 57.0, "pack_count": 20, "unit_price": 2.85, "strength_mg": 120.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "EASY SLIM 120MG 10 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EUROPEAN EGYPTIAN PHARM. IND.", "price_egp": 30.0, "pack_count": 10, "unit_price": 3.0, "strength_mg": 120.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ORLISTYLE 120 MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "COPAD PHARMA", "price_egp": 105.0, "pack_count": 30, "unit_price": 3.5, "strength_mg": 120.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "FINSHAPE 120MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MASH PREMIERE", "price_egp": 240.0, "pack_count": 30, "unit_price": 8.0, "strength_mg": 120.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "QUICK-SLIM 120 MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MARCYRL PHARMACEUTICAL INDUSTRIES (MPI)", "price_egp": 240.0, "pack_count": 30, "unit_price": 8.0, "strength_mg": 120.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ORLISMART 120 MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "PHAROPHARMA", "price_egp": 249.0, "pack_count": 30, "unit_price": 8.3, "strength_mg": 120.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ORLISTAT 120 MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA > OCTOBER PHARMA", "price_egp": 249.0, "pack_count": 30, "unit_price": 8.3, "strength_mg": 120.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "obesity" }, { "id": 1272, "generic": "Semaglutide", "line": 2, "is_adjunct": false, "form": "injection", "strength_mg": 2.4, "adult_dose": "Subcutaneous once weekly, escalating over 16 weeks: 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then a maintenance dose of 2.4 mg once weekly", "adult_duration": "Long-term alongside a reduced-calorie diet and increased physical activity; review benefit at 6 months", "dose_source": "eMC SmPC, Wegovy 2.4 mg FlexTouch solution for injection (Novo Nordisk), sections 4.1 and 4.2", "rationale": "14 live Egyptian products and the drug patients are asking for by name. The SmPC indication is weight management at BMI 30 or above, or BMI 27 to under 30 with at least one weight-related comorbidity - and this condition has three free slots with only orlistat in it.", "cautions": [ "The oral semaglutide tablets on the Egyptian market (3 mg, 7 mg, 14 mg) are licensed for type 2 diabetes, NOT for weight management - the two are not interchangeable, and the doses are unrelated.", "Stop immediately and investigate for pancreatitis if there is persistent severe abdominal pain.", "Nausea, vomiting and diarrhoea can cause dehydration and acute kidney injury - counsel on fluid intake and slow the escalation rather than pushing through.", "Gallstones in about 1.6% - the risk rises with rapid weight loss.", "Weight is regained after stopping unless diet and activity changes have been established.", "Cost is a genuine barrier in Egypt; discuss it before starting rather than after the first pen." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Adolescents 12 years and over with obesity and body weight above 60 kg use the same weekly escalation to a maximum of 2.4 mg. Stop if BMI has not fallen by at least 5% after 12 weeks. Not established below 12 years.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": [ { "label": "12 years and over", "age_min_months": 144, "age_max_months": 216, "dose_text": "Over 60 kg body weight: the same weekly escalation as an adult, to a maximum of 2.4 mg. Stop if BMI has not fallen by at least 5% after 12 weeks." } ], "peds_doses": null, "brands": [ { "trade_name": "WEGOVY 2.4 MG FLEXTOUCH PEN", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "NOVO NORDISK > NOVO NORDISK SCIENTIFIC OFFICE", "price_egp": 13612.0, "pack_count": null, "unit_price": null, "strength_mg": 2.4, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "obesity" } ] }